Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Minerva Neurosciences Fell Over 28% Today

By Maxx Chatsko - Updated Oct 1, 2019 at 3:13PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A cyberattack resulted in a clinical trial delay. Really.

What happened

Shares of Minerva Neurosciences (NERV -6.59%) tumbled more than 28% today after the company provided an update on the status of three pipeline assets. The biggest news was that a phase 3 trial evaluating the company's lead drug candidate, MIN-101 (roluperidone), was delayed after a cyberattack on a contractor handling patient recruitment disrupted enrollment. 

Minerva Neurosciences now expects the late-stage trial, studying MIN-101 as a potential treatment for negative symptoms of schizophrenia, to deliver top-line results in the first half of 2020. The results were originally expected before the end of 2019. 

As of 2:10 p.m. EDT, the pharmaceutical stock had settled to a 26.8% loss.

A declining chart drawn on a chalkboard.

Image source: Getty Images.

So what

A cyberattack on a contractor is beyond the company's control. Nonetheless, investors are worried that the resulting delay in the trial for its lead drug candidate might have material consequences for Minerva. 

The phase 3 trial for MIN-101 comprises two parts. In the first part, patients will be randomly assigned to receive MIN-101 or placebo for 12 weeks. The results from this initial period are the "top line results" that are now expected in the first half of 2020. In the second part, patients that were receiving the drug candidate will continue to receive the same dose, while patients that received placebo for the first part of the study will be switched to receive one of two doses of the drug candidate. Patients will be tracked for another 40 weeks, meaning the entire phase 3 trial will have an observation period spanning 52 weeks.

The delay isn't necessarily a big deal in the grand scheme of things, but Minerva had planned its financial runway around having top-line results before the end of 2019. The business ended June with $69 million in cash and had burned through $20 million in the first six months of 2019. 

Now what

The delay for the phase 3 trial for MIN-101 in schizophrenia means the company may not be able to raise additional cash with potentially favorable top-line results in hand. That could mean a stock offering conducted at a lower share price than previously expected, which could mean more shares will need to be offered to raise the same amount of money -- leading to more dilution for investors.

None of this will matter once the results from the study are announced, which is the event that will ultimately dictate the direction of the stock price. But many investors aren't willing to stick around now that the end-of-year catalyst has been delayed.

Maxx Chatsko has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Minerva Neurosciences, Inc. Stock Quote
Minerva Neurosciences, Inc.
NERV
$3.18 (-6.59%) $0.22

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
397%
 
S&P 500 Returns
128%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/19/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.